Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma.

[1]  N. Keiding,et al.  Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. , 2009, Scandinavian journal of haematology.

[2]  R. Liang,et al.  Secondary central nervous system involvement by non‐Hodgkin's lymphoma: The risk factors , 2006, Hematological oncology.

[3]  I. Flinn,et al.  High-dose therapy and blood or marrow transplantation for non-Hodgkin lymphoma with central nervous system involvement. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  W. Wilson,et al.  High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. , 2005, Blood.

[5]  S. Adachi,et al.  Rapid Improvement of Paraplegia Caused by Epidural Involvements of Burkitt’s Lymphoma With Chemotherapy , 2004, Spine.

[6]  M. Hino,et al.  Successful treatment with reduced-intensity stem cell transplantation in a case of relapsed refractory central nervous system lymphoma , 2003, Annals of Hematology.

[7]  K. Aldape,et al.  Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. , 2003, Blood.

[8]  E. Franssen,et al.  CNS Prophylaxis and Treatment in Non-Hodgkin's Lymphoma: Variation in Practice and Lessons from the Literature , 2003, Leukemia & lymphoma.

[9]  Y. Ishigatsubo,et al.  Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non‐hodgkin lymphoma , 2002, Cancer.

[10]  S. Kvaløy,et al.  Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  E. Thiel,et al.  CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes , 2002, Neurology.

[12]  L. Deangelis,et al.  A better way to find tumor in the CSF? , 2002, Neurology.

[13]  J. Streater,et al.  Intrathecal Chemotherapy alone is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin's Lymphoma , 2002, Leukemia & lymphoma.

[14]  I. Lossos,et al.  Central Nervous System Relapse of Systemic Non-Hodgkin's Lymphoma: Results of Treatment Based on High-dose Methotrexate Combination Chemotherapy , 2002, Leukemia & lymphoma.

[15]  T. Batchelor,et al.  High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphoma. , 2001, Clinical lymphoma.

[16]  K. Hoang-Xuan,et al.  Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Tilly,et al.  Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients , 2000 .

[18]  S. Horning,et al.  High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  H Fujita,et al.  Predictive Factors for Central Nervous System Involvement in Non-Hodgkin's Lymphoma: Significance of Very High Serum LDH Concentrations , 2000, Leukemia & lymphoma.

[20]  S. Phuphanich,et al.  Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C Tondini,et al.  Diffuse large-cell lymphoma of the testis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Twijnstra,et al.  Presenting features and value of diagnostic procedures in leptomeningeal metastases , 1999, Neurology.

[23]  F. Gherlinzoni,et al.  Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. , 1999, Leukemia & lymphoma.

[24]  J. Shinoda,et al.  Increased levels of CSF soluble CD27 in patients with primary central nervous system lymphoma. , 1998, Cancer letters.

[25]  L. Recht,et al.  High-dose intravenous methotrexate for patients with nonleukemic leptomeningeal cancer: is intrathecal chemotherapy necessary? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  P. Mclaughlin,et al.  Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. , 1998, Blood.

[27]  B. Cole,et al.  Cerebrospinal fluid cytology in patients with cancer , 1998, Cancer.

[28]  J. Hermans,et al.  Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. , 1997, Archives of neurology.

[29]  K. van Besien,et al.  Central nervous system relapse of lymphoid malignancies in adults: the role of high-dose chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  B. Andersson,et al.  Impact of preexisting CNS involvement on the outcome of bone marrow transplantation in adult hematologic malignancies. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Stamatoullas,et al.  Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. , 1996, Bone marrow transplantation.

[32]  M. Kersten,et al.  Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies. , 1996, Blood.

[33]  A. Goldstone,et al.  Autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma and CNS involvement: those transplanted with active CNS disease have a poor outcome--a report by the European Bone Marrow Transplant Lymphoma Registry. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Emili Montserrat,et al.  A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[35]  D. Ettinger,et al.  Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Weisenburger,et al.  Central Nervous System Involvement in Patients with Diffuse Aggressive Non‐Hodgkin's Lymphoma , 1991, American journal of clinical oncology.

[37]  K. Wallner,et al.  Reversal of cranial nerve dysfunction with radiation therapy in adults with lymphoma and leukemia. , 1990, International journal of radiation oncology, biology, physics.

[38]  H. Kirshner,et al.  Successful chemotherapeutic treatment of epidural compression in non‐Hodgkin's lymphoma , 1982, Cancer.

[39]  H. Yokoo,et al.  Intraepithelial carcinoma concomitant with esophageal carcinoma , 1962, Cancer.

[40]  T. Batchelor,et al.  Metastatic neurologic complications of non-Hodgkin’s lymphoma , 2005, Current oncology reports.

[41]  I. Schmidt-Wolf,et al.  Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. , 2004, Haematologica.

[42]  T. Molina,et al.  Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  V. Levin,et al.  Cancer in the nervous system , 1996 .

[44]  K. Thorling,et al.  Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis. , 1996, Acta oncologica.

[45]  J. Coindre,et al.  Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A study of 30 cases in a series of 498 patients. , 1987, Oncology.